Mylan (MYL) is marketing a long-acting version of the best-selling Lantus insulin — which the company named Semglee — for adults with Type 2 diabetes, and adults and children with Type 1 diabetes.

Mylan CEO Heather Bresch commented, "Today's decision by the U.S. Patent and Trademark Appeal Board invalidating Sanofi's Lantus device patents is another significant milestone clearing the ...

Mylan’s hopes of grabbing a slice of the big US market for insulin glargine – the active ingredient in Sanofi’s Lantus blockbuster – have been dealt a blow. The FDA has issued a second ...

Mylan sought approval for generic version of Sanofi's SoloStar Generic maker won on challenges to several Sanofi patents Court rejects Sanofi's appeal of decisions (Reuters) - A U.S. appeals court ...

(Reuters) - U.S. generics drugmaker Mylan said on Thursday that the United States Patent and Trademark Office had rejected Sanofi's infringement claims relating to insulin drug Lantus. Sanofi is ...

Mylan has launched a biosimilar version of Sanofi’s best-selling insulin, Lantus, that it says is priced 65 percent lower than comparable insulins. The biosimilar, called Semglee, costs $147.98 ...

Lantus – said to be the most administered ... The FDA approval was awarded to Mylan, which is now part of Viatris after merging with Pfizer's Upjohn division last year.

Already under fire from one Lantus challenger, Sanofi is suing Mylan in an effort to hold off that company's version of its top-selling drug. Sanofi says Mylan is infringing 18 patents and asked ...

Semglee has an identical amino acid sequence to Sanofi's Lantus® and is approved for the same indications. Semglee, co-developed by Mylan and Biocon Biologics, was approved as a drug product ...

Mylan Commences Phase III Clinical Trials for its Generic Version of Advair Diskus(R) and Insulin Analog to Lantus(R) PITTSBURGH, Sept. 16, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL), one of ...

long-acting insulin Lantus (insulin glargine 100 U/mL), clearing one hurdle for Mylan's generic versions. Patent infringement litigation is still open with no specific trial date determined.